Amedisys, Inc. (NASDAQ:AMED) Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC raised its position in Amedisys, Inc. (NASDAQ:AMED) by 72.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,947 shares of the health services provider’s stock after purchasing an additional 27,353 shares during the period. Squarepoint Ops LLC’s holdings in Amedisys were worth $5,962,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Banque Cantonale Vaudoise acquired a new stake in Amedisys during the first quarter worth approximately $60,000. Innealta Capital LLC acquired a new position in Amedisys in the second quarter valued at $64,000. Covestor Ltd lifted its position in Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after buying an additional 447 shares during the period. Signaturefd LLC boosted its stake in Amedisys by 88.2% in the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after buying an additional 530 shares during the last quarter. Finally, GAM Holding AG purchased a new stake in Amedisys in the 2nd quarter valued at about $275,000. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Stock Performance

Shares of AMED stock opened at $96.63 on Monday. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30. The company has a market cap of $3.16 billion, a PE ratio of -150.98, a P/E/G ratio of 1.90 and a beta of 0.78. The company’s fifty day simple moving average is $97.61 and its 200-day simple moving average is $94.98. Amedisys, Inc. has a 52 week low of $89.55 and a 52 week high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.10. The company had revenue of $591.19 million during the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.66 EPS for the current year.

Analyst Upgrades and Downgrades

AMED has been the subject of several research analyst reports. William Blair lowered shares of Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price on the stock. in a research report on Monday, July 29th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $100.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.